Cytosorbents (NASDAQ:CTSO) Issues Quarterly Earnings Results

Cytosorbents (NASDAQ:CTSO - Get Free Report) issued its quarterly earnings results on Monday. The medical research company reported ($0.03) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.07) by $0.04, Zacks reports. Cytosorbents had a negative return on equity of 118.54% and a negative net margin of 49.47%. The business had revenue of $9.20 million during the quarter, compared to analyst estimates of $10.09 million.

Cytosorbents Price Performance

Shares of CTSO traded down $0.02 during mid-day trading on Friday, hitting $0.97. 151,955 shares of the stock were exchanged, compared to its average volume of 143,808. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The company has a market cap of $53.04 million, a PE ratio of -2.69 and a beta of 0.78. Cytosorbents has a 52-week low of $0.70 and a 52-week high of $1.61. The firm has a 50-day moving average of $1.07 and a two-hundred day moving average of $1.05.

Analyst Ratings Changes

CTSO has been the topic of a number of research analyst reports. D. Boral Capital reissued a "buy" rating and issued a $10.00 price target on shares of Cytosorbents in a report on Tuesday. StockNews.com began coverage on shares of Cytosorbents in a report on Thursday. They issued a "hold" rating on the stock. Finally, HC Wainwright reiterated a "neutral" rating and issued a $1.00 price target on shares of Cytosorbents in a report on Thursday. Two equities research analysts have rated the stock with a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $4.67.

Remove Ads

About Cytosorbents

Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.